Canada - English - Health Canada

bayer inc - riociguat - tablet - 1mg - riociguat 1mg - vasodilating agents

Singapore - English - HSA (Health Sciences Authority)

bayer (south east asia) pte ltd - riociguat micronized - tablet, film coated - 1mg - riociguat micronized 1mg

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

bayer co. (malaysia) sdn. bhd. - riociguat -

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer ag, germany - riociguat - film-coated tablet - 1 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

bayer pharma ag - riociguat - film-coated tablet - 1 mg

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

bayer ag - riociguat - riociguat....1mg

European Union - English - EMA (European Medicines Agency)

bayer ag - riociguat - hypertension, pulmonary - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah) adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Israel - English - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 0.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Israel - English - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 0.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.

Israel - English - Ministry of Health

bayer israel ltd - riociguat - film coated tablets - riociguat 1.5 mg - riociguat - chronic thromboembolic pulmonary hypertension (cteph) adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii with • inoperable cteph, • persistent or recurrent cteph after surgical treatment, to improve exercise capacity. pulmonary arterial hypertension (pah)adempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity.efficacy has been shown in a pah population including aetiologies of idiopathic or heritable pah or pah associated with connective tissue disease.